India’s pharmaceutical sector, valued at Rs 4,17,345 crore (USD 61.36 billion) in 2023–24, is the world’s third largest by quantity and fourteenth by worth. The trade provides 20% of world generic medicines and over 50% of world vaccine demand. In April 2025, it grew 7.8% year-on-year, pushed by robust home demand and innovation.
With a market capitalization of Rs 27,063.49 crore, the shares of Piramal Pharma Ltd closed at Rs 203.60 per share, growing round 0.58 % as in comparison with the earlier closing value of Rs 202.43 apiece.
Piramal Pharma, in its FY25 annual report, unveiled its FY30 imaginative and prescient focusing on over 3x EBITDA development with a 25% margin and greater than 2x total income improve.
It goals for $1.2 billion CDMO income at 25% margin, $600 million from complicated hospital generics with 25%+ margin, and $200 million from client well being, sustaining double-digit margins.
Wanting ahead to the corporate’s monetary efficiency, income elevated by 8 % from Rs 2,552 crore in Q4FY24 to Rs 2,754 crore in Q4FY25. Additional, throughout the identical time-frame, web revenue elevated by 52 % from Rs 101 crore to Rs 154 crore.
Piramal Pharma’s CDMO section posted robust development with revenues rising 19% in FY24 and 15% in FY25. Innovation-related and differentiated choices grew considerably, supported by $90 million in capability expansions.
In Advanced Hospital Generics, Piramal maintained management in Sevoflurane and Baclofen within the US, whereas increasing into RoW (Remainder of the World) markets with new capability.
Client Healthcare crossed ₹1,000 crore in income, pushed by energy manufacturers, aggressive SKU launches, and digital-first methods, regardless of regulatory value cuts on key merchandise like i-pill
For FY26, Piramal Pharma anticipates mid-single-digit consolidated income development and a moderated EBITDA margin within the mid-teens, down from 17% in FY25. That is attributed to lowered ordering from a significant on-patent CDMO buyer as a consequence of stock normalization. Regardless of this, PAT is anticipated to develop modestly, supported by a decrease tax fee from improved abroad facility utilization.
Piramal Pharma Restricted which provides a portfolio of differentiated pharma merchandise throughout a home and international distribution community. The Firm has roughly 17 international amenities and a worldwide distribution community in over 100 international locations.
Written by Abhishek Singh
Disclaimer
The views and funding ideas expressed by funding consultants/broking homes/score businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of monetary losses. Traders should subsequently train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Personal Restricted or the writer are usually not accountable for any losses brought about on account of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
